{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:55:02Z","timestamp":1762509302848,"version":"build-2065373602"},"reference-count":9,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>A 78-year-old woman with a history of follicular lymphoma treated with obinutuzumab and bendamustine developed Merkel cell carcinoma (MCC) on her left forearm. After surgical excision, in-transit and lymph node metastases appeared within three weeks. Avelumab and radiotherapy were initiated, but severe neutropenia occurred after two doses, requiring G-CSF support and treatment discontinuation. Despite early cessation, metastatic lesions regressed. This case suggests that prior B-cell\u2013directed therapy may increase the risk of hematologic toxicity with immune checkpoint inhibitors and that even short-term avelumab may induce a durable response in MCC.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1672282","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T05:26:52Z","timestamp":1759987612000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Severe neutropenia induced by avelumab in a patient with Merkel cell carcinoma"],"prefix":"10.3389","volume":"16","author":[{"given":"Eri","family":"Ohta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayo","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitomi","family":"Fujimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natsuko","family":"Saito-Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etsuko","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/cup.13910","article-title":"Merkel cell carcinoma: A review","volume":"48","author":"Walsh","year":"2021","journal-title":"J Cutan Pathol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e15292","DOI":"10.1111\/dth.15292","article-title":"Merkel cell carcinoma: An updated review of pathogenesis, diagnosis, and treatment options","volume":"35","author":"Hernandez","year":"2022","journal-title":"Dermatol Ther"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30364-3","article-title":"Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial","volume":"17","author":"Kaufman","year":"2016","journal-title":"Lancet Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"103464","DOI":"10.1016\/j.critrevonc.2021.103464","article-title":"Efficacy and safety profile of avelumab monotherapy","volume":"166","author":"Zhao","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1386838","article-title":"PD-L1 blockade immunotherapy rewires cancer-induced emergency myelopoiesis","volume":"15","author":"Boumpas","year":"2024","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009016","article-title":"Hematologic complications of immune checkpoint inhibitors","volume":"139","author":"Kroll","year":"2022","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1270398","article-title":"Stromal cell inhibition of anti-CD20 antibody mediated killing of B-cell Malignancies","volume":"11","author":"Fagnano","year":"2023","journal-title":"Front Cell Dev Biol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1110748","article-title":"Bendamustine associated immune suppression and infections during therapy of hematological Malignancies","volume":"57","author":"Gafter-Gvili","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"B9","article-title":"Merkel cell carcinoma arising in a patient with a history of multiple Malignancies","volume":"90","author":"Stevenson","year":"2012","journal-title":"Cutis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1672282\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T05:26:53Z","timestamp":1759987613000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1672282\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":9,"alternative-id":["10.3389\/fimmu.2025.1672282"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1672282","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,9]]},"article-number":"1672282"}}